Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Angelo Antonini, A. Jon Stoessl, Leah S. Kleinman, Anne M. Skalicky, Thomas S. Marshall, Kavita R. Sail, Koray Onuk & Per Lars Anders Odin. (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion 34:12, pages 2063-2073.
Read now
Read now
Julia Lowin, Kavita Sail, Rakhi Baj, Yash J. Jalundhwala, Thomas S. Marshall, Henrietta Konwea & K. R. Chaudhuri. (2017) The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. Journal of Medical Economics 20:11, pages 1207-1215.
Read now
Read now
Kjell Fuxe, Diego Guidolin, Luigi F Agnati & Dasiel O Borroto-Escuela. (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opinion on Therapeutic Targets 19:3, pages 377-398.
Read now
Read now
Sabine Skodda. (2014) Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease. Journal of Parkinsonism and Restless Legs Syndrome 4, pages 53-62.
Read now
Read now
Karoline Wenzel, Carl Nikolaus Homann, Giovanni Fabbrini & Carlo Colosimo. (2014) The role of subcutaneous infusion of apomorphine in Parkinson’s disease. Expert Review of Neurotherapeutics 14:7, pages 833-843.
Read now
Read now
Livia Dézsi & László Vécsei. (2014) Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. Expert Opinion on Drug Metabolism & Toxicology 10:3, pages 409-424.
Read now
Read now
David J Pedrosa & Lars Timmermann. (2013) Review: management of Parkinson’s disease. Neuropsychiatric Disease and Treatment 9, pages 321-340.
Read now
Read now
Brenton A Wright & Cheryl H Waters. (2013) Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease. Expert Review of Neurotherapeutics 13:6, pages 719-729.
Read now
Read now
H.H. Fernandez & P. Odin. (2011) Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Current Medical Research and Opinion 27:5, pages 907-919.
Read now
Read now
Nelida Fernandez, Juan J Garcia, Maria Jose Diez, Ana M Sahagun, Raquel Díez & Matilde Sierra. (2010) Effects of dietary factors on levodopa pharmacokinetics. Expert Opinion on Drug Metabolism & Toxicology 6:5, pages 633-642.
Read now
Read now
Articles from other publishers (55)
Z. Pirtošek, V. Leta, P. Jenner & M. Vérin. (2023) Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?. Journal of Neural Transmission 130:11, pages 1395-1404.
Crossref
Crossref
Harmen R. Moes, Tove Henriksen, Jarosław Sławek, Onanong Phokaewvarangkul, Erik Buskens & Teus van Laar. (2023) Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review. Journal of Neural Transmission 130:11, pages 1359-1377.
Crossref
Crossref
Teus van Laar, K. Ray Chaudhuri, Angelo Antonini, Tove Henriksen & Maja Trošt. (2023) Infusion Therapies in the Treatment of Parkinson’s Disease. Journal of Parkinson's Disease 13:5, pages 641-657.
Crossref
Crossref
Angelo Antonini, Rajesh Pahwa, Per Odin, Stuart H. Isaacson, Aristide Merola, Lin Wang, Prasanna L. Kandukuri, Ali Alobaidi, Connie H. Yan, Yanjun Bao, Cindy Zadikoff, Juan Carlos Parra, Lars Bergmann & K. Ray Chaudhuri. (2022) Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis. CNS Drugs 36:12, pages 1269-1283.
Crossref
Crossref
Komal Latif, Aman Ullah, Anastasiia D. Shkodina, Dmytro I. Boiko, Zakia Rafique, Badrah S. Alghamdi, Mohamed A. Alfaleh & Ghulam Md. Ashraf. (2022) Drug reprofiling history and potential therapies against Parkinson’s disease. Frontiers in Pharmacology 13.
Crossref
Crossref
Hazhir Teymourian, Farshad Tehrani, Katherine Longardner, Kuldeep Mahato, Tatiana Podhajny, Jong-Min Moon, Yugender Goud Kotagiri, Juliane R. Sempionatto, Irene Litvan & Joseph Wang. (2022) Closing the loop for patients with Parkinson disease: where are we?. Nature Reviews Neurology 18:8, pages 497-507.
Crossref
Crossref
D. Santos-García, M.J. Catalán, V. Puente, F. Valldeoriola, I. Regidor, P. Mir, J. Matías-Arbelo, J.C. Parra & F. Grandas. (2021) Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community. Neurología (English Edition) 36:2, pages 101-111.
Crossref
Crossref
D. Santos-García, M.J. Catalán, V. Puente, F. Valldeoriola, I. Regidor, P. Mir, J. Matías-Arbelo, J.C. Parra & F. Grandas. (2021) Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas. Neurología 36:2, pages 101-111.
Crossref
Crossref
Nicki Niemann, Andrew Billnitzer & Joseph Jankovic. (2021) Parkinson's disease and skin. Parkinsonism & Related Disorders 82, pages 61-76.
Crossref
Crossref
Roongroj Bhidayasiri, Onanong Phokaewvarangkul, Kamolwan Boonpang, Thanatat Boonmongkol, Yuwadee Thongchuem, Nitinan Kantachadvanich & Pedro J. García Ruiz. (2019) Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy. Clinical Neuropharmacology 42:5, pages 172-178.
Crossref
Crossref
Ignacio Regidor, Diego Santos-García, Mar;ıa José Catalán, Vıctor Puente, Francesc Valldeoriola, Francisco Grandas, Pablo Mir, Juan Carlos Parra & José Matías Arbelo. (2019) Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. Journal of Parkinson's Disease 9:1, pages 173-182.
Crossref
Crossref
Adrian Hall, Laurent Provins & Anne Valade. (2018)
Novel Strategies To Activate the Dopamine D
1
Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation
. Journal of Medicinal Chemistry 62:1, pages 128-140.
Crossref
Crossref
Angelo Antonini & Bianca Nitu. (2018) Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. Journal of Neural Transmission 125:8, pages 1131-1135.
Crossref
Crossref
Angelo Antonini, Elena Moro, Clecio Godeiro & Heinz Reichmann. (2018) Medical and surgical management of advanced Parkinson's disease. Movement Disorders 33:6, pages 900-908.
Crossref
Crossref
Maria José Catalán, Angelo Antonini, Matilde Calopa, Ovidiu Băjenaru, Oriol de Fábregues, Adolfo Mínguez-Castellanos, Per Odin, José Manuel García-Moreno, Stephen W. Pedersen, Zvezdan Pirtošek & Jaime Kulisevsky. (2017) Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. eNeurologicalSci 8, pages 44-53.
Crossref
Crossref
Carsten Buhmann, R. Hilker, P. Lingor, C. Schrader, J. Schwarz, M. Wolz & H. Reichmann. (2017) Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. Journal of Neural Transmission 124:8, pages 1005-1013.
Crossref
Crossref
G. Salazar, J. Martín, M. Fragoso & M.A. Font. (2017) Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability. Neurología (English Edition) 32:6, pages 407-410.
Crossref
Crossref
G. Salazar, J. Martín, M. Fragoso & M.A. Font. (2017) Apomorfina en bomba de perfusión continua en pacientes con enfermedad de Parkinson avanzada con diferente grado de afectación funcional. Neurología 32:6, pages 407-410.
Crossref
Crossref
Matej Skorvanek & Kailash P. Bhatia. (2017) The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues. Movement Disorders Clinical Practice 4:1, pages 21-31.
Crossref
Crossref
Carlos Pérez-López, Albert Samà, Daniel Rodríguez-Martín, Andreu Català, Joan Cabestany, Juan Moreno-Arostegui, Eva de Mingo & Alejandro Rodríguez-Molinero. (2016) Assessing Motor Fluctuations in Parkinson’s Disease Patients Based on a Single Inertial Sensor. Sensors 16:12, pages 2132.
Crossref
Crossref
Anna De Rosa, Alessandro Tessitore, Leonilda Bilo, Silvio Peluso & Giuseppe De Michele. (2016) Infusion treatments and deep brain stimulation in Parkinson's Disease: The role of nursing. Geriatric Nursing 37:6, pages 434-439.
Crossref
Crossref
O. Băjenaru, A. Ene, B. O. Popescu, J. A. Szász, M. Sabău, D. F. Mureşan, L. Perju-Dumbrava, C. D. Popescu, A. Constantinescu, I. Buraga & M. Simu. (2015) The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience. Journal of Neural Transmission 123:4, pages 407-414.
Crossref
Crossref
Carlos Pérez-López, Albert Samà, Daniel Rodríguez-Martín, Juan Manuel Moreno-Aróstegui, Joan Cabestany, Angels Bayes, Berta Mestre, Sheila Alcaine, Paola Quispe, Gearóid Ó. Laighin, Dean Sweeney, Leo R. Quinlan, Timothy J. Counihan, Patrick Browne, Roberta Annicchiarico, Alberto Costa, Hadas Lewy & Alejandro Rodríguez-Molinero. (2016) Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer. Artificial Intelligence in Medicine 67, pages 47-56.
Crossref
Crossref
Gabriel Salazar, Marta Fragoso, Jonatan Martí, Noelia Martín & Rosó Bernal. (2016) Continuous Apomorphine Infusion in Patients with Advanced Parkinson’s Disease with Varying Degrees of Functional Impairment. Journal of Behavioral and Brain Science 06:10, pages 393-403.
Crossref
Crossref
Rejko Krüger, Rüdiger Hilker, Christian Winkler, Michael Lorrain, Matthias Hahne, Christoph Redecker, Paul Lingor & Wolfgang H. Jost. (2015) Advanced stages of PD: interventional therapies and related patient-centered care. Journal of Neural Transmission 123:1, pages 31-43.
Crossref
Crossref
Oluwadamilola O Ojo & Hubert H Fernandez. (2015) Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease. Future Neurology 10:3, pages 191-201.
Crossref
Crossref
S. Picciolini, N. Castagnetti, R. Vanna, D. Mehn, M. Bedoni, F. Gramatica, M. Villani, D. Calestani, M. Pavesi, L. Lazzarini, A. Zappettini & C. Morasso. (2015) Branched gold nanoparticles on ZnO 3D architecture as biomedical SERS sensors. RSC Advances 5:113, pages 93644-93651.
Crossref
Crossref
Xiaojia Ni, Shaonan Liu, Fuchang Lu, Xiaogeng Shi & Xinfeng Guo. (2014) Efficacy and Safety of Tai Chi for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE 9:6, pages e99377.
Crossref
Crossref
Mariachiara Sensi, F. Preda, L. Trevisani, E. Contini, D. Gragnaniello, J. G. Capone, E. Sette, N. Golfre-Andreasi, V. Tugnoli, M. R. Tola & R. Quatrale. (2014) Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. Journal of Neural Transmission 121:6, pages 633-642.
Crossref
Crossref
Panagiotis Zis, Kallol Ray Chaudhuri & Michael Samuel. 2014. Levodopa-Induced Dyskinesia in Parkinson's Disease. Levodopa-Induced Dyskinesia in Parkinson's Disease
1
16
.
J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra & R. Yañez. (2013) Advanced Parkinson's disease: Clinical characteristics and treatment. Part II. Neurología (English Edition) 28:9, pages 558-583.
Crossref
Crossref
J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra & R. Yañez. (2013) Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II. Neurología 28:9, pages 558-583.
Crossref
Crossref
C. Warren Olanow & Anthony H. V. Schapira. (2013) Therapeutic prospects for Parkinson disease. Annals of Neurology 74:3, pages 337-347.
Crossref
Crossref
Peter Jenner. (2013) Wearing Off, Dyskinesia, and the Use of Continuous Drug Delivery in Parkinson's Disease. Neurologic Clinics 31:3, pages S17-S35.
Crossref
Crossref
Anastasia N. Kaminioti, Georgios T. Nikitas, Apostolos K. Terlis, Athanasios G. Manolis, Thomas Thomaides & Aggeliki N. Panousopoulou. (2013) Ventricular Bigeminy after Subcutaneous Administration of Apomorphine in a Patient with Refractory Parkinson’s Disease: A Case Report. Journal of Movement Disorders 6:1, pages 9-12.
Crossref
Crossref
Dag Nyholm, Per Odin, Anders Johansson, Krai Chatamra, Charles Locke, Sandeep Dutta & Ahmed A. Othman. (2012) Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients. The AAPS Journal 15:2, pages 316-323.
Crossref
Crossref
Hubert H. Fernandez, Arvydas Vanagunas, Per Odin, Alberto J. Espay, Robert A. Hauser, David G. Standaert, Krai Chatamra, Janet Benesh, Yili Pritchett, Steven L. Hass & Robert A. Lenz. (2013) Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism & Related Disorders 19:3, pages 339-345.
Crossref
Crossref
Manuela Pilleri, Konstantinos Koutsikos & Angelo Antonini. (2012) Is there room for new non-dopaminergic treatments in Parkinson’s disease?. Journal of Neural Transmission 120:2, pages 349-352.
Crossref
Crossref
O. Gershanik & P. Jenner. (2012) Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease. European Journal of Neurology 19:12, pages 1502-1508.
Crossref
Crossref
Yoland Smith, Thomas Wichmann, Stewart A Factor & Mahlon R DeLong. (2011) Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa. Neuropsychopharmacology 37:1, pages 213-246.
Crossref
Crossref
S. Maranis, S. Tsouli & S. Konitsiotis. (2011) Treatment of motor symptoms in advanced Parkinson's disease: A practical approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:8, pages 1795-1807.
Crossref
Crossref
Maria Cruz Rodriguez-Oroz, Concepción Marin & Oriol de Fabregues. (2011) Continuous Dopaminergic Stimulation. The Neurologist 17, pages S30-S37.
Crossref
Crossref
Lawrence ElmerRobert A Hauser. (2011) Strategies for Parkinson’s disease care: prevention and management of motor fluctuations. Neurodegenerative Disease Management 1:5, pages 415-430.
Crossref
Crossref
Rüdiger Hilker, Angelo Antonini & Per Odin. (2010) What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?. Journal of Neural Transmission 118:6, pages 907-914.
Crossref
Crossref
Angelo Antonini, Ioannis U. Isaias, Giorgia Rodolfi, Andrea Landi, Francesca Natuzzi, Chiara Siri & Gianni Pezzoli. (2010) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. Journal of Neurology 258:4, pages 579-585.
Crossref
Crossref
Aristide Merola, Maurizio Zibetti, Serena Angrisano, Laura Rizzi, Michele Lanotte & Leonardo Lopiano. (2011) Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Movement Disorders 26:4, pages 664-670.
Crossref
Crossref
Mark J. Millan. (2010) From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacology & Therapeutics 128:2, pages 229-273.
Crossref
Crossref
D. Santos-García, M. Macías, M. LLaneza, L. Fuster-Sanjurjo, A. Echarri-Piudo, S. Belmonte & S. Blanco. (2010) Experiencia con la infusión continua de levodopa intraduodenal (Duodopa®) en pacientes con enfermedad de Parkinson avanzada en un hospital de segundo nivel asistencial. Neurología 25:9, pages 536-543.
Crossref
Crossref
Angelo Antonini, Giulia Ursino, Daniela Calandrella, Laura Bernardi & Mauro Plebani. (2010) Continuous dopaminergic delivery in Parkinson’s disease. Journal of Neurology 257:S2, pages 305-308.
Crossref
Crossref
Alessandro StefaniMariangela PierantozziGiacomo KochSalvatore GalatiPaolo Stanzione. (2010) Therapy for dyskinesias in Parkinson’s disease patients. Future Neurology 5:2, pages 277-299.
Crossref
Crossref
Angelo Antonini, K. Ray Chaudhuri, Pablo Martinez-Martin & Per Odin. (2010) Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs Disease. CNS Drugs 24:2, pages 119-129.
Crossref
Crossref
Hong Yuan, Zhen-Wen Zhang, Li-Wu Liang, Quan Shen, Xiang-Dang Wang, Su-Mei Ren, Hong-Jie Ma, Shu-Jun Jiao & Ping Liu. (2010) Treatment strategies for Parkinson’s disease帕金森氏病的治疗策略. Neuroscience Bulletin 26:1, pages 66-76.
Crossref
Crossref
G. GrimaldiM. Manto. (2010) “Old” and emerging Therapies of Human Tremor. Clinical Medicine Insights: Therapeutics 2, pages CMT.S2999.
Crossref
Crossref
D. Santos-García, M. Macías, M. Llaneza, L. Fuster-Sanjurjo, A. Echarri-Piudo, S. Belmonte & S. Blanco. (2010) Experience with continuous levodopa enteral infusion (Duodopa®)in patients with advanced Parkinson's disease in a secondary level hospital. Neurología (English Edition) 25:9, pages 536-543.
Crossref
Crossref
Angelo Antonini & Per Odin. (2009) Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism & Related Disorders 15, pages S97-S100.
Crossref
Crossref